Nippon Universal Of Japan To Add Sales Staff For Parent Zydus Generics
This article was originally published in PharmAsia News
Executive Summary
Japan's Nippon Universal Pharmaceutical, a subsidiary of India's Zydus, plans an expansion within Japan, increasing its medical representative staff from 30 to 50. Although Zydus specializes in generics, the new staff members are to handle new drugs that result from a partnership between Zydus and Eli Lilly of the United States. Nippon Universal plans to introduce as many as six generics to have a portfolio of more than 30 drugs by the end of this year. Zydus also is considering handling generics made by other drug makers in addition to its own line. (Click here for more - a subscription may be required
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.